DURGA POUDEL: Open Payments
NPI 1184454373 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,966 in 99 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $544 · 2025 $1,966
Food & beverage: $1,966
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $381 |
| Janssen Pharmaceuticals, Inc | 11 | $352 |
| Alkermes, Inc. | 17 | $321 |
| E.R. Squibb & Sons, L.L.C. | 13 | $284 |
| Teva Pharmaceuticals USA, Inc. | 11 | $260 |
| Otsuka America Pharmaceutical, Inc. | 11 | $144 |
| Neurocrine BioSciences, Inc. | 3 | $70 |
| Lundbeck LLC | 3 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Vanda Pharmaceuticals Inc. | 2 | $32 |
Products named: VRAYLAR, ARISTADA, COBENFY, INVEGA SUSTENNA, REXULTI, AUSTEDO XR, SPRAVATO, UZEDY.
Industry payments across MO — which companies pay providers there.
